{"To": [0], "provide": [1, 246], "updated": [2], "recommendations": [3, 52], "about": [4, 249], "prophylaxis": [5, 62, 219], "and": [6, 16, 27, 49, 63, 65, 91, 113, 154, 176, 193, 223, 242, 252], "treatment": [7, 64, 81, 174], "of": [8, 29, 74, 82, 102, 133, 254], "venous": [9], "thromboembolism": [10], "(VTE)": [11], "in": [12, 84, 109, 125, 171], "patients": [13, 85, 110, 127, 164, 190], "with": [14, 86, 98, 105, 111, 128, 142, 151, 165, 191, 210, 233], "cancer.PubMed": [15], "the": [17, 47, 80, 172, 177, 250], "Cochrane": [18], "Library": [19], "were": [20], "searched": [21], "for": [22, 79, 123, 161, 207, 225, 239], "randomized": [23], "controlled": [24], "trials": [25], "(RCTs)": [26], "meta-analyses": [28], "RCTs": [30, 73, 119], "published": [31], "from": [32], "August": [33], "1,": [34], "2014,": [35], "through": [36], "December": [37], "4,": [38], "2018.": [39], "ASCO": [40], "convened": [41], "an": [42, 194], "Expert": [43], "Panel": [44], "to": [45, 135, 147, 229], "review": [46, 56], "evidence": [48], "revise": [50], "previous": [51, 136], "as": [53, 159], "needed.The": [54], "systematic": [55], "included": [57], "35": [58], "publications": [59, 67], "on": [60, 68, 121], "VTE": [61, 69, 83, 162, 173, 240], "18": [66], "risk": [70, 101, 132], "assessment.": [71], "Two": [72, 117], "direct": [75], "oral": [76], "anticoagulants": [77], "(DOACs)": [78], "cancer": [87, 129, 192, 215, 234], "reported": [88, 120], "that": [89], "edoxaban": [90, 155], "rivaroxaban": [92, 153], "are": [93, 96, 168], "effective": [94], "but": [95], "linked": [97], "a": [99], "higher": [100], "bleeding": [103], "compared": [104], "low-molecular-weight": [106], "heparin": [107], "(LMWH)": [108], "GI": [112], "potentially": [114], "genitourinary": [115], "cancers.": [116], "additional": [118], "DOACs": [122], "thromboprophylaxis": [124, 141, 199], "ambulatory": [126], "at": [130, 226, 259], "increased": [131], "VTE.Changes": [134], "recommendations:": [137, 187], "Clinicians": [138], "may": [139], "offer": [140], "apixaban,": [143], "rivaroxaban,": [144], "or": [145], "LMWH": [146, 182], "selected": [148], "high-risk": [149], "outpatients": [150, 209], "cancer;": [152], "have": [156], "been": [157, 184], "added": [158], "options": [160], "treatment;": [163], "brain": [166], "metastases": [167], "now": [169], "addressed": [170], "section;": [175], "recommendation": [178], "regarding": [179], "long-term": [180], "postoperative": [181], "has": [183], "expanded.": [185], "Re-affirmed": [186], "Most": [188], "hospitalized": [189], "acute": [195], "medical": [196], "condition": [197], "require": [198], "throughout": [200], "hospitalization.": [201], "Thromboprophylaxis": [202], "is": [203, 257], "not": [204], "routinely": [205], "recommended": [206], "all": [208], "cancer.": [211], "Patients": [212, 232], "undergoing": [213], "major": [214], "surgery": [216, 222], "should": [217, 235, 245], "receive": [218], "starting": [220], "before": [221], "continuing": [224], "least": [227], "7": [228], "10": [230], "days.": [231], "be": [236], "periodically": [237], "assessed": [238], "risk,": [241], "oncology": [243], "professionals": [244], "patient": [247], "education": [248], "signs": [251], "symptoms": [253], "VTE.Additional": [255], "information": [256], "available": [258], "www.asco.org/supportive-care-guidelines.": [260]}